ArticleTherapeutics and clinical risk management2010
Management of ANCA-associated vasculitis: Current trends and future prospects.
Article in Therapeutics and clinical risk management, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 44 citations in OpenAlex.
- Myelopathy Due to Hypertrophic Pachymeningitis Associated With ANCA Vasculitis: A 10-Year Follow-up Case Report.Korean journal of neurotrauma · 2024Article
- Unravelling the Link between the Gut Microbiome and Autoimmune Kidney Diseases: A Potential New Therapeutic Approach.International journal of molecular sciences · 2024Review
- Avacopan, a Novel Competitive C5a Receptor Antagonist, for Severe Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.Clinical drug investigation · 2023Review
- The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study.Annals of the rheumatic diseases · 2022Article
- Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course.European journal of rheumatology · 2022Article
- Neutrophil Extracellular Traps: A Potential Therapeutic Target in MPO-ANCA Associated Vasculitis?Frontiers in immunology · 2021Review
- A Comparison of Immunoglobulin Variable Region N-Linked Glycosylation in Healthy Donors, Autoimmune Disease and Lymphoma.Frontiers in immunology · 2020Review
- Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study.BMC nephrology · 2019Article
- Article
- Sweet syndrome: a rare feature of ANCA-associated vasculitis or unusual consequence of azathioprine-induced treatment.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2018Article
- Antineutrophil cytoplasmic antibody-associated vasculitis, update on molecular pathogenesis, diagnosis, and treatment.International journal of nephrology and renovascular disease · 2018Review
- Stress and Disease Onset in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Frontiers in psychiatry · 2017Article
- Therapy and prognosis of ANCA-associated vasculitis from the clinical nephrologist's perspective.International urology and nephrology · 2017Review
- Familial vasculitides: granulomatosis with polyangitis and microscopic polyangitis in two brothers with differing anti-neutrophil cytoplasm antibody specificity.Clinical kidney journal · 2016Article
- Unusual cause of flare in antineutrophil cytoplasmic antibody-associated vasculitis.BMJ case reports · 2016Article
- Fatal pulmonary complication during induction therapy in a patient with ANCA-associated vasculitis.Acta medica Lituanic · 2016Article
- Vasculitic Neuropathies.Current treatment options in neurology · 2015Article
- A physician survey reveals differences in management of idiopathic pulmonary hemosiderosis.Orphanet journal of rare diseases · 2015Article
- Necrotizing and crescentic glomerulonephritis presenting with preserved renal function in patients with underlying multisystem autoimmune disease: a retrospective case series.Rheumatology (Oxford, England) · 2015Article
- Issues in trial design for ANCA-associated and large-vessel vasculitis.Nature reviews. Rheumatology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antineutrophil cytoplasm antibody (ANCA)-associated vasculitides are a spectrum of heterogeneous autoimmune diseases characterized by necrotizing small vessel vasculitis and the presence of ANCA. These chronic multisystem disorders may be life-threatening if there is major organ involvement, such as acute renal failure or pulmonary hemorrhage, and require significant initial immunosuppression and long-term maintenance treatment. Long-established protocols using cyclophosphamide and prednisolone have resulted in dramatically improved outcomes for patients since the 1970s. Subsequently, international collaboration has contributed to a growing evidence base and consensus in the management of these rare disorders. Modifications to traditional treatment protocols by the use of azathioprine or methotrexate rather than cyclophosphamide, and the introduction of newer agents, such as rituximab, has maintained outcomes whilst decreasing toxicity. However, the treatment limitations of incomplete efficacy, infection, and cumulative toxicity persist. These issues have continued to drive the search for safer and more effective modulation of the immune system using targeted immunotherapy. This review will explore the current evidence base for management of ANCA-associated vasculitis and future treatment prospects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.